Literature DB >> 1307347

Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.

J Morita1, M Yoshino, H Watari, I Yoshida, T Motohiro, F Yamashita, Y Okano, T Hashimoto.   

Abstract

Wilson's disease is an autosomal recessive disorder characterized by an accumulation of a toxic amount of copper in the body. Triethylene tetramine dihydrochloride (trientine, 2HCl) is a new chelating agent that may be effective in the removal of excess copper but long-term efficacy has not yet been investigated. Here we report the use of trientine over more than 8 years in 2 patients with Wilson's disease who could not tolerate D-penicillamine. We found no significant side effect, except a decreased serum iron concentration without clinical symptoms of anemia. In annual examinations at a steady state, the serum copper levels remained below 20 micrograms/100 ml. The 24-hour urinary copper excretion was less than that found using D-penicillamine, while the basal copper excretion, after 5 days abstinence from trientine, was maintained below 100 micrograms/day. Both hepatic and neurological manifestations except bulbar symptoms were recovered without any initial deterioration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1307347     DOI: 10.1159/000457456

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  6 in total

Review 1.  Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.

Authors:  Garth J S Cooper
Journal:  Drugs       Date:  2011-07-09       Impact factor: 9.546

2.  A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.

Authors:  G J S Cooper; A A Young; G D Gamble; C J Occleshaw; A M Dissanayake; B R Cowan; D H Brunton; J R Baker; A R J Phillips; C M Frampton; S D Poppitt; R N Doughty
Journal:  Diabetologia       Date:  2009-01-27       Impact factor: 10.122

Review 3.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 4.  Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature.

Authors:  Rachel M Taylor; Yuan Chen; Anil Dhawan
Journal:  Eur J Pediatr       Date:  2008-12-09       Impact factor: 3.183

5.  Case report: concordant traumatic brainstem contusion delayed diagnosis in a young man with Wilson's disease.

Authors:  A Marcus; C Ammermann; M Klein; M H Schmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  1995-01       Impact factor: 4.785

Review 6.  Advances in Treatment of Wilson Disease.

Authors:  Annu Aggarwal; Mohit Bhatt
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.